These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 8401177)

  • 1. Role of interleukin-1 inhibitory molecules in therapy of acute and chronic myelogenous leukemia.
    Estrov Z; Kurzrock R; Talpaz M
    Leuk Lymphoma; 1993 Aug; 10(6):407-18. PubMed ID: 8401177
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interleukin-1 and its inhibitors: a biologic and therapeutic model for the role of growth regulatory factors in leukemias.
    Kurzrock R; Wetzler M; Estrov Z; Talpaz M
    Cytokines Mol Ther; 1995 Sep; 1(3):177-84. PubMed ID: 9384674
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Suppression of chronic myelogenous leukemia colony growth by interleukin-1 (IL-1) receptor antagonist and soluble IL-1 receptors: a novel application for inhibitors of IL-1 activity.
    Estrov Z; Kurzrock R; Wetzler M; Kantarjian H; Blake M; Harris D; Gutterman JU; Talpaz M
    Blood; 1991 Sep; 78(6):1476-84. PubMed ID: 1715791
    [TBL] [Abstract][Full Text] [Related]  

  • 4. B-lineage lymphoid blast crisis in juvenile chronic myelogenous leukemia: II. Interleukin-1-mediated autocrine growth regulation of the lymphoblasts.
    Attias D; Grunberger T; Vanek W; Estrov Z; Cohen A; Lau R; Freedman MH
    Leukemia; 1995 May; 9(5):884-8. PubMed ID: 7769852
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interruption of autocrine and paracrine growth-stimulatory mechanisms: a new therapeutic strategy for chronic myelogenous leukemia.
    Estrov Z
    Semin Hematol; 1993 Jul; 30(3 Suppl 3):35-6. PubMed ID: 7694373
    [No Abstract]   [Full Text] [Related]  

  • 6. Role of suramin as an IL-1 inhibitor in suppression of acute myelogenous leukemia progenitor proliferation.
    Estrov Z; Talpaz M; Estey EH; Strassmann G
    Exp Hematol; 1995 Sep; 23(10):1080-7. PubMed ID: 7544738
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Altered levels of interleukin-1 beta and interleukin-1 receptor antagonist in chronic myelogenous leukemia: clinical and prognostic correlates.
    Wetzler M; Kurzrock R; Estrov Z; Kantarjian H; Gisslinger H; Underbrink MP; Talpaz M
    Blood; 1994 Nov; 84(9):3142-7. PubMed ID: 7949186
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Suppression of juvenile chronic myelogenous leukemia colony growth by interleukin-1 receptor antagonist.
    Schirò R; Longoni D; Rossi V; Maglia O; Doni A; Arsura M; Carrara G; Masera G; Vannier E; Dinarello CA
    Blood; 1994 Jan; 83(2):460-5. PubMed ID: 8286744
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of interleukin-1 beta converting enzyme inhibitor on acute myelogenous leukemia progenitor proliferation.
    Estrov Z; Black RA; Sleath PR; Harris D; Van Q; LaPushin R; Estey EH; Talpaz M
    Blood; 1995 Dec; 86(12):4594-602. PubMed ID: 8541550
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of interleukin-1 in disease.
    Dinarello CA; Wolff SM
    N Engl J Med; 1993 Jan; 328(2):106-13. PubMed ID: 8439348
    [No Abstract]   [Full Text] [Related]  

  • 11. Leukemia inhibitory factor in long-term adherent layer cultures: increased levels of bioactive protein in leukemia and modulation by IL-4, IL-1 beta, and TNF-alpha.
    Wetzler M; Estrov Z; Talpaz M; Kim KJ; Alphonso M; Srinivasan R; Kurzrock R
    Cancer Res; 1994 Apr; 54(7):1837-42. PubMed ID: 8137298
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of autologous natural killer cells in chronic myelogenous leukemia.
    Pierson BA; Miller JS
    Leuk Lymphoma; 1997 Nov; 27(5-6):387-99. PubMed ID: 9477121
    [TBL] [Abstract][Full Text] [Related]  

  • 13. BCR-ABL-induced deregulation of the IL-33/ST2 pathway in CD34+ progenitors from chronic myeloid leukemia patients.
    Levescot A; Flamant S; Basbous S; Jacomet F; Féraud O; Anne Bourgeois E; Bonnet ML; Giraud C; Roy L; Barra A; Chomel JC; Turhan A; Guilhot F; Girard JP; Gombert JM; Herbelin A
    Cancer Res; 2014 May; 74(10):2669-76. PubMed ID: 24675360
    [TBL] [Abstract][Full Text] [Related]  

  • 14. SCF, IL-1beta, IL-1ra and GM-CSF in the bone marrow and serum of normal individuals and of AML and CML patients.
    Tao M; Li B; Nayini J; Andrews CB; Huang RW; Devemy E; Song S; Venugopal P; Preisler HD
    Cytokine; 2000 Jun; 12(6):699-707. PubMed ID: 10843748
    [TBL] [Abstract][Full Text] [Related]  

  • 15. FTY720, a new alternative for treating blast crisis chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphocytic leukemia.
    Neviani P; Santhanam R; Oaks JJ; Eiring AM; Notari M; Blaser BW; Liu S; Trotta R; Muthusamy N; Gambacorti-Passerini C; Druker BJ; Cortes J; Marcucci G; Chen CS; Verrills NM; Roy DC; Caligiuri MA; Bloomfield CD; Byrd JC; Perrotti D
    J Clin Invest; 2007 Sep; 117(9):2408-21. PubMed ID: 17717597
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differential effects of TGF-beta 1 on normal and leukemic human hematopoietic cell proliferation.
    Murohashi I; Endho K; Nishida S; Yoshida S; Jinnai I; Bessho M; Hirashima K
    Exp Hematol; 1995 Aug; 23(9):970-7. PubMed ID: 7543418
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical grade expansion of CD45RA, CD45RO, and CD62L-positive T-cell lines from HLA-compatible donors: high cytotoxic potential against AML and ALL cells.
    Barbui AM; Borleri G; Conti E; Ciocca A; Salvi A; Micò C; Introna M; Rambaldi A
    Exp Hematol; 2006 Apr; 34(4):475-85. PubMed ID: 16569594
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differential response to stem cell factor and Flt3 ligand by the FAB subtype in acute myeloid leukemia clonogenic cells.
    Murohashi I; Yoshida K; Kishimoto K; Takahashi T; Wakao D; Jinnai I; Yagasaki F; Kawai N; Suzuki T; Matsuda A; Hirashima K; Bessho M
    J Interferon Cytokine Res; 2002 Mar; 22(3):335-41. PubMed ID: 12034041
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Participation of the cytokines interleukin 6, tumor necrosis factor-alpha, and interleukin 1-beta secreted by acute myelogenous leukemia blasts in autocrine and paracrine leukemia growth control.
    Oster W; Cicco NA; Klein H; Hirano T; Kishimoto T; Lindemann A; Mertelsmann RH; Herrmann F
    J Clin Invest; 1989 Aug; 84(2):451-7. PubMed ID: 2788173
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of natural killer cells in the treatment of chronic myeloid leukemia.
    Silla LM; Whiteside TL; Ball ED
    J Hematother; 1995 Aug; 4(4):269-79. PubMed ID: 7489141
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.